immunology

News
AbbVieHQ

More good news for AbbVie in rheumatoid arthritis

AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.

Events
Immuno-Oncology
Partner Content

Immuno-Oncology

Immuno-Oncology Main Conference: 26 – 27 September 2018 Pre-Conference Workshops: 25 September 2018 Copthorne Tara Hotel, London, UK

News
Samsung Bioepis' Remicade rival approved in EU

Samsung Bioepis' Remicade rival approved in EU

Merck, Sharp and Dohme's (MSD) inflammatory diseases blockbuster Remicade (infliximab) faces further biosimilar competition after Samsung Bioepis' rival, Flixabi, was approved in Europe.